MCID: AMP003
MIFTS: 35

Ampulla of Vater Neoplasm malady

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Ampulla of Vater Neoplasm

Aliases & Descriptions for Ampulla of Vater Neoplasm:

Name: Ampulla of Vater Neoplasm 12 14
Carcinoma of Ampulla of Vater 12 69
Ampulla of Vater Carcinoma 12 14
Ampullary Carcinoma 12 56
Carcinoma of the Ampulla of Vater 56
Tumor of the Ampulla of Vater 12
Neoplasm of Ampulla of Vater 69
Ampulla of Vater Cancer 12
Ampulloma 56

Characteristics:

Orphanet epidemiological data:

56
carcinoma of the ampulla of vater
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:10022 DOID:4932
NCIt 47 C4443 C3908
SNOMED-CT 64 126858004 254609000
Orphanet 56 ORPHA300557
ICD10 via Orphanet 34 C24.1
UMLS via Orphanet 70 C0262401
ICD10 33 C24.1

Summaries for Ampulla of Vater Neoplasm

Disease Ontology : 12 An ampulla of Vater cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary : Ampulla of Vater Neoplasm, also known as carcinoma of ampulla of vater, is related to neuroendocrine tumor and large cell neuroendocrine carcinoma. An important gene associated with Ampulla of Vater Neoplasm is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are O-linked glycosylation and Diseases of glycosylation. The drugs Pancrelipase and Epinephrine have been mentioned in the context of this disorder. Related phenotype is Increased shRNA abundance (Z-score > 2).

Related Diseases for Ampulla of Vater Neoplasm

Diseases related to Ampulla of Vater Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 177)
id Related Disease Score Top Affiliating Genes
1 neuroendocrine tumor 30.0 CDX2 KRT20
2 large cell neuroendocrine carcinoma 30.0 CDX2 KRAS KRT20 SST
3 ampulla of vater adenocarcinoma 11.1
4 ampulla of vater squamous cell carcinoma 11.1
5 ampulla of vater adenosquamous carcinoma 11.1
6 malignant skin fibrous histiocytoma 10.3 HRAS KRAS
7 severe pre-eclampsia 10.3 HRAS KRAS
8 erythrocyte lactate transporter defect 10.3 HRAS KRAS
9 melanocytic nevus syndrome, congenital, somatic 10.3 HRAS KRAS
10 bile duct disease 10.3 HRAS KRAS
11 biliary papillomatosis 10.3 KRAS MUC1
12 choroid epithelioid cell melanoma 10.3 CDX2 MUC2
13 syndactyly-polydactyly-earlobe syndrome 10.3 HRAS KRAS
14 uterine ligament mucinous adenocarcinoma 10.3 CDX2 KRAS
15 laryngeal mucoepidermoid carcinoma 10.3 MUC1 MUC2
16 gonococcal seminal vesiculitis 10.3 HRAS KRAS
17 testicular granulosa cell tumor 10.2 HRAS MUC1
18 exposure keratitis 10.2 CDX2 MUC2
19 agenesis and aplasia of uterine body 10.2 KRAS KRT20
20 motor neuron disease 10.2 MUC1 MUC6
21 lethal congenital contracture syndrome 10.2 CDX2 MUC1
22 kidney clear cell sarcoma 10.2 HRAS KRAS
23 ascending colon cancer 10.2 KRT20 MUC2
24 cervical serous adenocarcinoma 10.2 HRAS KRAS
25 skeletal-extraskeletal angiomatosis 10.2 MUC1 SYP
26 prolactin producing pituitary tumor 10.2 MUC1 SYP
27 papilloma 10.2 MUC1 MUC6
28 cauda equina intradural extramedullary astrocytoma 10.2 HRAS MUC1
29 peritoneal benign neoplasm 10.2 CDX2 KRT20
30 dystonia 10.2 CDX2 KRT20
31 anal canal paget's disease 10.2 CDX2 KRT20
32 autosomal recessive stickler syndrome 10.2 MUC1 SYP
33 synovitis 10.2 CDX2 SYP
34 precursor t-lymphoblastic lymphoma/leukemia 10.2 HRAS KRAS MUC1
35 microinvasive cervical squamous cell carcinoma 10.2 MUC1 SYP
36 corneal intraepithelial neoplasm 10.2 MUC1 SYP
37 bone deterioration disease 10.2 KRAS SYP
38 dental caries 10.2 HRAS KRAS MUC1
39 nasal cavity disease 10.2 HRAS KRAS MUC1
40 extramedullary plasmacytoma 10.2 CDX2 KRT20
41 behcet's syndrome arthropathy 10.2 MUC1 SYP
42 paroxysmal nocturnal hemoglobinuria 10.2 HRAS KRAS MUC1
43 postpoliomyelitis syndrome 10.2 CDX2 HRAS KRAS
44 pearson syndrome 10.2 HRAS KRAS MUC1
45 trachea squamous cell carcinoma 10.2 HRAS KRAS MUC1
46 aneurysm of sinus of valsalva 10.2 MUC1 SYP
47 polyp of corpus uteri 10.2 KRAS SST
48 ideomotor apraxia 10.2 CDX2 HRAS KRAS
49 ureter adenocarcinoma 10.2 CDX2 KRAS MUC2
50 ovarian squamous cell carcinoma 10.2 KRT20 MUC6

Graphical network of the top 20 diseases related to Ampulla of Vater Neoplasm:



Diseases related to Ampulla of Vater Neoplasm

Symptoms & Phenotypes for Ampulla of Vater Neoplasm

GenomeRNAi Phenotypes related to Ampulla of Vater Neoplasm according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.74 KRT17
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.74 KRAS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.74 KRAS
4 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.74 KRT17
5 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.74 KRAS
6 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.74 KRT17
7 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.74 KRAS
8 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.74 HRAS
9 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.74 KRT17
10 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.74 KRT17 HRAS KRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.74 KRT17
12 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.74 KRT17
13 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.74 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.74 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.74 KRT17
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.74 HRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.74 KRT17
18 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.74 KRT17
19 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.74 KRAS KRT17
20 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.74 KRAS
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.74 KRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.74 HRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.74 KRAS
24 Decreased viability GR00055-A-2 9.7 HRAS KRAS MUC1
25 Decreased viability GR00106-A-0 9.7 KRAS
26 Decreased viability GR00221-A-1 9.7 HRAS KRAS
27 Decreased viability GR00221-A-2 9.7 HRAS KRAS
28 Decreased viability GR00221-A-3 9.7 HRAS
29 Decreased viability GR00301-A 9.7 KRAS
30 Decreased viability GR00381-A-1 9.7 KRAS

Drugs & Therapeutics for Ampulla of Vater Neoplasm

Drugs for Ampulla of Vater Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved Phase 3,Phase 1 53608-75-6
2
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
3 pancreatin Phase 3,Phase 1
4 Epinephryl borate Phase 3
5 Racepinephrine Phase 3
6
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
7
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599, 9887054 43805
8
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
9
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
10
Levoleucovorin Approved Phase 2,Phase 1 68538-85-2
11
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
12
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
13
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
14
Bevacizumab Approved, Investigational Phase 2 216974-75-3
15
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
16
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 54575, 6560146 143
19
Camptothecin Experimental Phase 1, Phase 2 7689-03-4
20 Antimetabolites Phase 2,Phase 1
21 Antimetabolites, Antineoplastic Phase 2,Phase 1
22 Antidotes Phase 2,Phase 1
23 Anti-Infective Agents Phase 2,Phase 1
24 Antiviral Agents Phase 2,Phase 1
25 Calcium, Dietary Phase 2,Phase 1
26 Immunosuppressive Agents Phase 2,Phase 1
27 Liver Extracts Phase 2,Phase 1
28 Micronutrients Phase 2,Phase 1
29 Protective Agents Phase 2,Phase 1
30 Trace Elements Phase 2,Phase 1
31 Vitamin B Complex Phase 2,Phase 1
32 Vitamins Phase 2,Phase 1
33 Folic Acid Antagonists Phase 1, Phase 2
34 Nucleic Acid Synthesis Inhibitors Phase 1, Phase 2
35 Antineoplastic Agents, Phytogenic Phase 1, Phase 2
36 topoisomerase I inhibitors Phase 1, Phase 2
37 Topoisomerase Inhibitors Phase 1, Phase 2
38 Albumin-Bound Paclitaxel Phase 1, Phase 2
39 Antimitotic Agents Phase 1, Phase 2
40 Angiogenesis Inhibitors Phase 2
41 Angiogenesis Modulating Agents Phase 2
42 Antibodies Phase 2
43 Antibodies, Monoclonal Phase 2
44 Immunoglobulins Phase 2
45
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
46 Protein Kinase Inhibitors Phase 2
47 Folate Nutraceutical Phase 2,Phase 1
48 Vitamin B9 Nutraceutical Phase 2,Phase 1
49 Chelating Agents
50 Gastrointestinal Agents

Interventional clinical trials:

(show all 30)
id Name Status NCT ID Phase
1 Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study Unknown status NCT01737463 Phase 4
2 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
3 Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy Completed NCT00830778 Phase 3
4 Comparison on the Efficacy of Endoscopic Snare Papillectomy With or Without Submucosal Injection Completed NCT02165852 Phase 3
5 Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method Recruiting NCT02916199 Phase 3
6 Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2
7 Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00009893 Phase 2
8 Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types Completed NCT00633789 Phase 2
9 Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00059865 Phase 1, Phase 2
10 Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer Recruiting NCT02333188 Phase 1, Phase 2
11 Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Active, not recruiting NCT01208103 Phase 2
12 CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater Active, not recruiting NCT01202409 Phase 2
13 The Use of Cap-assisted Forward Viewing Endoscopy for Examination of the Ampulla of Vater Not yet recruiting NCT02867826 Phase 2
14 Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers Terminated NCT00832637 Phase 2
15 Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers Completed NCT00183846 Phase 1
16 Endoscopic Papillectomy for Early Ampullary Tumors: Long-term Results of the First Large Multicenter Prospective Study Completed NCT01764503
17 Endoscopic Ultrasound Staging of Periampullary Neoplasms: Retrospective Completed NCT00880633
18 Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation Completed NCT02477228
19 Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma Completed NCT00495924
20 Loop-tipped Guidewire in Selective Biliary Cannulation Completed NCT02028845
21 Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy Completed NCT00841607
22 A Population-Based Case-Control Study of Biliary Tract Cancers in Shanghai, China Completed NCT00339560
23 Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers Completed NCT01134276
24 Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients Completed NCT01718821
25 Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Completed NCT02081131
26 Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions Recruiting NCT01750619
27 Enteral Nutrition After Pancreaticoduodenectomy Recruiting NCT03150615
28 High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Recruiting NCT02757859
29 Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study Terminated NCT00100321
30 Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Trial on Standard Open Versus Minimally Invasive Surgery Withdrawn NCT01712971

Search NIH Clinical Center for Ampulla of Vater Neoplasm

Genetic Tests for Ampulla of Vater Neoplasm

Anatomical Context for Ampulla of Vater Neoplasm

Publications for Ampulla of Vater Neoplasm

Variations for Ampulla of Vater Neoplasm

Expression for Ampulla of Vater Neoplasm

Search GEO for disease gene expression data for Ampulla of Vater Neoplasm.

Pathways for Ampulla of Vater Neoplasm

Pathways related to Ampulla of Vater Neoplasm according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.9 MUC1 MUC2 MUC6
2
Show member pathways
11.6 MUC1 MUC2 MUC6
3
Show member pathways
11.43 HRAS KRAS MUC1 MUC2 MUC6
4
Show member pathways
11.17 MUC1 MUC2 MUC6
5 11.07 HRAS KRAS
6 11 HRAS KRAS
7 10.99 HRAS KRAS
8
Show member pathways
10.96 HRAS KRAS
9 10.94 HRAS KRAS
10
Show member pathways
10.85 HRAS KRAS
11 10.77 HRAS KRAS
12 10.71 HRAS KRAS
13 10.62 HRAS KRAS
14 10.27 HRAS KRAS

GO Terms for Ampulla of Vater Neoplasm

Cellular components related to Ampulla of Vater Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC6

Biological processes related to Ampulla of Vater Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intermediate filament organization GO:0045109 9.37 KRT17 KRT20
2 O-glycan processing GO:0016266 9.33 MUC1 MUC2 MUC6
3 maintenance of gastrointestinal epithelium GO:0030277 9.32 MUC2 MUC6
4 response to isolation stress GO:0035900 9.26 HRAS KRAS
5 regulation of long-term neuronal synaptic plasticity GO:0048169 9.13 HRAS KRAS SYP
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 HRAS KRAS MUC1 MUC2 MUC6

Sources for Ampulla of Vater Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....